MiNK Therapeutics shared a post on LinkedIn about their recent publication in Frontiers in Immunology by Magdalena Niedzielska et al.:
“We’re excited to share our latest publication in Frontiers in Immunology, highlighting the unique power of CAR-iNKT cells to overcome the barriers that limit traditional cell therapies – especially in solid tumors.
Unlike conventional CAR-T, iNKT cells combine precision targeting, innate immune activation, and off-the-shelf accessibility. Recent case reports and ongoing trials continue to demonstrate encouraging activity in heavily pre-treated, immunotherapy-resistant cancers.
This paper reinforces the promise of MiNK’s platform to reshape the future of cancer treatment.
Read the publication.”
Title: CAR-iNKT cells: redefining the frontiers of cellular immunotherapy
Journal: Frontiers in Immunology
Authors: Magdalena Niedzielska, Amy Chalmers, Martyna C. Popis, Efrat Altman-Sharoni, Stephen Addis, Rebekka Beulen, Nils-Petter Rudqvist, Eleni Chantzoura, Marco A. Purbhoo, Dhan Chand, Mark A. Exley
More posts featuring MiNK Therapeutics on OncoDaily.